Sichuan Huiyu Pharmaceutical (SHA:688553) will conduct clinical trials on the drug HY-2003 after obtaining approval from the Chinese drug administration, according to a Shanghai Stock Exchange disclosure on Wednesday.
The drug contains deoxycholic acid, which aims to reduce adverse reactions at the injection site, shorten the medication interval, accelerate the onset time, and reduce the dosing cycle, the pharmaceutical company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.